Literature DB >> 30450578

Response to treatment is more important than disease severity at diagnosis for prediction of early relapse in new-onset paediatric Crohn's disease.

Tomer Ziv-Baran1, Séamus Hussey2, Malgorzata Sladek3, Jorge Amil Dias4, Javier Martin de Carpi5, Erasmo Miele6, Gabor Veres7, Paolo Lionetti8, Sibylle Koletzko9, Federica Nuti10, Anders Paerregaard11, Kaija-Leena Kolho12, Richard K Russell13, Ron Shaoul14, Dror Weiner1, Rotem Sigall Boneh1, Johanna Escher15, Lenne Finnby16, Dan Turner17, Arie Levine1.   

Abstract

BACKGROUND: Paediatric Crohn's disease is characteried by frequently relapsing disease which may lead to hospitalisations and complications. AIM: To develop predictive models for early relapse following first remission.
METHODS: The GROWTH CD prospective inception cohort was designed to predict risk for early disease relapse and poor outcomes. Newly diagnosed children underwent endoscopies and imaging. They were phenotyped and followed at scheduled visits through 78 weeks for relapses. Twenty-eight dichotomous and continuous variables were assessed at baseline and week 12, including phenotype, inflammatory markers, disease activity (PCDAI) and other markers. Clinical relapses defined as PCDAI >10 after remission were recorded using a relapse form. Logistic regression & risk modelling was performed.
RESULTS: We enrolled 282 eligible patients of whom 178 (63.6%) patients achieved steroid free remission by week 12. Disease complications developed in 22/76(29%) of patients with relapse compared to 20/206 (9.7%) without relapse (P = 0.01). Multivariable analysis demonstrated that while variables from age/gender at diagnosis were not predictive, week 12 variables including PCDAI >5 (P = 0.02), CRP >20 mg/L (P = 0.02), and faecal calprotectin >400 µg/g (P = 0.03) as optimal cut-offs were associated with increased risk of relapse. A prediction model for patients in remission including gender, age, week 12 PCDAI, calprotectin and CRP had sensitivity 43%, specificity 92%, PPV 78%, NPV 71% for relapse.
CONCLUSIONS: Early relapses were associated with a higher risk for disease complications at followup. Relapse prediction based on week 12 disease activity or inflammation is superior to prediction using data from diagnosis.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30450578     DOI: 10.1111/apt.15016

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  International prospective observational study investigating the disease course and heterogeneity of paediatric-onset inflammatory bowel disease: the protocol of the PIBD-SETQuality inception cohort study.

Authors:  Martine A Aardoom; Polychronis Kemos; Irma Tindemans; Marina Aloi; Sibylle Koletzko; Arie Levine; Dan Turner; Gigi Veereman; Mattias Neyt; Richard K Russell; Thomas D Walters; Frank M Ruemmele; Janneke N Samsom; Nicholas M Croft; Lissy de Ridder
Journal:  BMJ Open       Date:  2020-07-01       Impact factor: 2.692

2.  Predictors of Response to Exclusive Enteral Nutrition in Newly Diagnosed Crohn´s Disease in Children: PRESENCE Study from SEGHNP.

Authors:  Melinda Moriczi; Gemma Pujol-Muncunill; Rafael Martín-Masot; Santiago Jiménez Treviño; Oscar Segarra Cantón; Carlos Ochoa Sangrador; Luis Peña Quintana; Daniel González Santana; Alejandro Rodríguez Martínez; Antonio Rosell Camps; Honorio Armas; Josefa Barrio; Rafael González de Caldas; Mónica Rodríguez Salas; Elena Balmaseda Serrano; Ester Donat Aliaga; Andrés Bodas Pinedo; Esther Vaquero Sosa; Raquel Vecino López; Alfonso Solar Boga; Ana Moreno Álvarez; César Sánchez Sánchez; Mar Tolín Hernani; Carolina Gutiérrez Junquera; Nazareth Martinón Torres; María Rosaura Leis Trabazo; Francisco Javier Eizaguirre; Mónica García Peris; Enrique Medina Benítez; Beatriz Fernández Caamaño; Ana María Vegas Álvarez; Laura Crespo Valderrábano; Carmen Alonso Vicente; Javier Rubio Santiago; Rafael Galera-Martínez; Ruth García-Romero; Ignacio Ros Arnal; Santiago Fernández Cebrián; Helena Lorenzo Garrido; Javier Francisco Viada Bris; Marta Velasco Rodríguez-Belvis; Juan Manuel Bartolomé Porro; Miriam Blanco Rodríguez; Patricia Barros García; Gonzalo Botija; Francisco José Chicano Marín; Enrique La Orden Izquierdo; Elena Crehuá-Gaudiza; Víctor Manuel Navas-López; Javier Martín-de-Carpi
Journal:  Nutrients       Date:  2020-04-07       Impact factor: 5.717

3.  Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn's disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course.

Authors:  Rachel E Harris; Marina Aloi; Lissy de Ridder; Nicholas M Croft; Sibylle Koletzko; Arie Levine; Dan Turner; Gigi Veereman; Mattias Neyt; Laetitia Bigot; Frank M Ruemmele; Richard K Russell
Journal:  BMJ Open       Date:  2020-07-01       Impact factor: 2.692

4.  Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.

Authors:  Sjoukje-Marije Haisma; Henkjan J Verkade; Rene Scheenstra; Hubert P J van der Doef; Frank A J A Bodewes; Patrick F van Rheenen
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-10       Impact factor: 2.839

5.  A simple-to-use nomogram to predict long term survival of patients undergoing coronary artery bypass grafting (CABG) using bilateral internal thoracic artery grafting technique.

Authors:  Tomer Ziv-Baran; Rephael Mohr; Dmitry Pevni; Yanai Ben-Gal
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

6.  Inflammatory Bowel Disease: A Personalized Approach.

Authors:  Anastasia Konidari; David Dickens; Munir Pirmohamed
Journal:  Front Pediatr       Date:  2021-02-11       Impact factor: 3.418

7.  Induction of Remission in Pediatric Crohn's Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index.

Authors:  Roma Herman; Paulina Dumnicka; Stanisław Pieczarkowski; Krzysztof Fyderek
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

8.  Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial.

Authors:  Marleen Bouhuys; Willem S Lexmond; Gerard Dijkstra; Triana Lobatón; Edouard Louis; Stephanie van Biervliet; Henk Groen; Jordi Guardiola; Patrick van Rheenen
Journal:  BMJ Open       Date:  2021-11-03       Impact factor: 2.692

9.  First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.

Authors:  Maria M E Jongsma; Martine A Aardoom; Martinus A Cozijnsen; Merel van Pieterson; Tim de Meij; Michael Groeneweg; Obbe F Norbruis; Victorien M Wolters; Herbert M van Wering; Iva Hojsak; Kaija-Leena Kolho; Thalia Hummel; Janneke Stapelbroek; Cathelijne van der Feen; Patrick F van Rheenen; Michiel P van Wijk; Sarah T A Teklenburg-Roord; Marco W J Schreurs; Dimitris Rizopoulos; Michail Doukas; Johanna C Escher; Janneke N Samsom; Lissy de Ridder
Journal:  Gut       Date:  2020-12-31       Impact factor: 23.059

10.  Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn's Disease Patients.

Authors:  Eun Sil Kim; Yiyoung Kwon; Yon Ho Choe; Mi Jin Kim
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.